Cyclerion Therapeutics (CYCN) EBIAT (2019 - 2025)
Cyclerion Therapeutics has reported EBIAT over the past 7 years, most recently at -$976000.0 for Q3 2025.
- Quarterly results put EBIAT at -$976000.0 for Q3 2025, down 34.99% from a year ago — trailing twelve months through Sep 2025 was -$2.2 million (up 59.14% YoY), and the annual figure for FY2024 was -$3.1 million, up 75.72%.
- EBIAT for Q3 2025 was -$976000.0 at Cyclerion Therapeutics, down from -$324000.0 in the prior quarter.
- Over the last five years, EBIAT for CYCN hit a ceiling of $44.1 million in Q4 2022 and a floor of -$16.2 million in Q2 2021.
- Median EBIAT over the past 5 years was -$4.2 million (2023), compared with a mean of -$3.3 million.
- Biggest five-year swings in EBIAT: skyrocketed 509.28% in 2022 and later tumbled 104.07% in 2023.
- Cyclerion Therapeutics' EBIAT stood at -$10.8 million in 2021, then skyrocketed by 509.28% to $44.1 million in 2022, then tumbled by 104.07% to -$1.8 million in 2023, then skyrocketed by 129.53% to $530000.0 in 2024, then tumbled by 284.15% to -$976000.0 in 2025.
- The last three reported values for EBIAT were -$976000.0 (Q3 2025), -$324000.0 (Q2 2025), and -$1.4 million (Q1 2025) per Business Quant data.